Impact of TP2 MRD and BMI on outcomes. TP2 MRD negativity was associated with significantly better 3-year DFS (84.5%; 95% CI, 73.1-95.9) (A) and OS (91.9%, 95% CI, 81.0-100.0) (B) compared with TP2 MRD positivity, with a 3-year DFS of 57.9% (95% CI, 39.7-76.2; P = .017) and an OS of 61.9% (95% CI, 44.1-79.6; P = .007). BMI ≥30 kg/m² was associated with significantly poorer 3-year DFS (53.3%, 95% CI, 28.1-78.6) (C) and OS (49.2%; 95% CI, 24.3-74.1) (D) compared with BMI <30 kg/m² with a 3-year DFS of 77.5% (95% CI, 67.1-87.9; P = .023) and an OS of 81.1% (95% CI, 71.4-90.8; P < .001). D1 is day 1 of protocol treatment.